Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.

While statins significantly reduce cholesterol levels and thereby reduce the risk of cardiovascular disease, the development of myopathy with statin use is a significant clinical side-effect. Recent guidelines recommend increasing inclusion criteria for statin treatment in diabetic individuals; howe...

Full description

Bibliographic Details
Main Authors: Irena A Rebalka, Matthew J Raleigh, Laelie A Snook, Alexandra N Rebalka, Rebecca EK MacPherson, David C Wright, Jonathan D Schertzer, Thomas J Hawke
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-07-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00095/full
id doaj-3ee13a09d08c48dd978a91d98abcdee5
record_format Article
spelling doaj-3ee13a09d08c48dd978a91d98abcdee52020-11-25T00:18:26ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922016-07-01710.3389/fendo.2016.00095211272Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.Irena A Rebalka0Matthew J Raleigh1Laelie A Snook2Alexandra N Rebalka3Rebecca EK MacPherson4David C Wright5Jonathan D Schertzer6Thomas J Hawke7McMaster UniversityMcMaster UniversityUniversity of GuelphMcMaster UniversityUniversity of GuelphUniversity of GuelphMcMaster UniversityMcMaster UniversityWhile statins significantly reduce cholesterol levels and thereby reduce the risk of cardiovascular disease, the development of myopathy with statin use is a significant clinical side-effect. Recent guidelines recommend increasing inclusion criteria for statin treatment in diabetic individuals; however, the impact of statins on skeletal muscle health in those with diabetes (who already suffer from impairments in muscle health) is ill-defined. Here we investigate the effects of Fluvastatin treatment on muscle health in wild-type and streptozotocin (STZ)-induced diabetic mice. Wild-type and STZ-diabetic mice received diet enriched with 600 mg/kg Fluvastatin or control chow for 24 days. Muscle morphology, intra and extracellular lipid levels, and lipid transporter content was investigated. Our findings indicate that short-term Fluvastatin administration induced a myopathy that was not exacerbated by the presence of STZ-induced diabetes. Fluvastatin significantly increased ectopic lipid deposition within the muscle of STZ-diabetic animals, findings that were not seen with diabetes or statin treatment alone. Consistent with this observation, only Fluvastatin-treated diabetic mice downregulated protein expression of lipid transporters FAT/CD36 and FABPpm in their skeletal muscle. No differences in FAT/CD36 or FABPpm mRNA content were observed. Altered lipid compartmentalization resultant of a downregulation in lipid transporter content in STZ-induced diabetic skeletal muscle was apparent in the current investigation. Given the association between ectopic lipid deposition in skeletal muscle and the development of insulin-resistance, our findings highlight the necessity for more thorough investigations into the impact of statins in humans with diabetes.http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00095/fullskeletal muscleMyopathyFluvastatinFABPpmFAT/CD36Ectopic lipids
collection DOAJ
language English
format Article
sources DOAJ
author Irena A Rebalka
Matthew J Raleigh
Laelie A Snook
Alexandra N Rebalka
Rebecca EK MacPherson
David C Wright
Jonathan D Schertzer
Thomas J Hawke
spellingShingle Irena A Rebalka
Matthew J Raleigh
Laelie A Snook
Alexandra N Rebalka
Rebecca EK MacPherson
David C Wright
Jonathan D Schertzer
Thomas J Hawke
Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
Frontiers in Endocrinology
skeletal muscle
Myopathy
Fluvastatin
FABPpm
FAT/CD36
Ectopic lipids
author_facet Irena A Rebalka
Matthew J Raleigh
Laelie A Snook
Alexandra N Rebalka
Rebecca EK MacPherson
David C Wright
Jonathan D Schertzer
Thomas J Hawke
author_sort Irena A Rebalka
title Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
title_short Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
title_full Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
title_fullStr Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
title_full_unstemmed Statin Therapy Alters Lipid Storage in Diabetic Skeletal Muscle.
title_sort statin therapy alters lipid storage in diabetic skeletal muscle.
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2016-07-01
description While statins significantly reduce cholesterol levels and thereby reduce the risk of cardiovascular disease, the development of myopathy with statin use is a significant clinical side-effect. Recent guidelines recommend increasing inclusion criteria for statin treatment in diabetic individuals; however, the impact of statins on skeletal muscle health in those with diabetes (who already suffer from impairments in muscle health) is ill-defined. Here we investigate the effects of Fluvastatin treatment on muscle health in wild-type and streptozotocin (STZ)-induced diabetic mice. Wild-type and STZ-diabetic mice received diet enriched with 600 mg/kg Fluvastatin or control chow for 24 days. Muscle morphology, intra and extracellular lipid levels, and lipid transporter content was investigated. Our findings indicate that short-term Fluvastatin administration induced a myopathy that was not exacerbated by the presence of STZ-induced diabetes. Fluvastatin significantly increased ectopic lipid deposition within the muscle of STZ-diabetic animals, findings that were not seen with diabetes or statin treatment alone. Consistent with this observation, only Fluvastatin-treated diabetic mice downregulated protein expression of lipid transporters FAT/CD36 and FABPpm in their skeletal muscle. No differences in FAT/CD36 or FABPpm mRNA content were observed. Altered lipid compartmentalization resultant of a downregulation in lipid transporter content in STZ-induced diabetic skeletal muscle was apparent in the current investigation. Given the association between ectopic lipid deposition in skeletal muscle and the development of insulin-resistance, our findings highlight the necessity for more thorough investigations into the impact of statins in humans with diabetes.
topic skeletal muscle
Myopathy
Fluvastatin
FABPpm
FAT/CD36
Ectopic lipids
url http://journal.frontiersin.org/Journal/10.3389/fendo.2016.00095/full
work_keys_str_mv AT irenaarebalka statintherapyalterslipidstorageindiabeticskeletalmuscle
AT matthewjraleigh statintherapyalterslipidstorageindiabeticskeletalmuscle
AT laelieasnook statintherapyalterslipidstorageindiabeticskeletalmuscle
AT alexandranrebalka statintherapyalterslipidstorageindiabeticskeletalmuscle
AT rebeccaekmacpherson statintherapyalterslipidstorageindiabeticskeletalmuscle
AT davidcwright statintherapyalterslipidstorageindiabeticskeletalmuscle
AT jonathandschertzer statintherapyalterslipidstorageindiabeticskeletalmuscle
AT thomasjhawke statintherapyalterslipidstorageindiabeticskeletalmuscle
_version_ 1725376619776835584